Regeneron Pharmaceuticals Inc. is seeing a notable uptick in its stock price, driven by positive market sentiment and key developments in the biotech sector.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is rising today, reflecting a 1.99% increase in its stock price, closing at CA$800.50. This upward momentum is attributed to favorable news regarding regulatory developments and market trends in gene editing and rare diseases.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$79.75B
P/E
19.2x
Div. yield
0.47%
Div. / share
$3.64
52W high
$859.34
52W low
$538.24
1W change
-4.09%
Beta
0.19
Analyst Price Targets
Based on 25 analysts covering REGN · as of Sep 17, 2026
Wall Street analysts forecast REGN stock price to rise 9.6% over the next 12 months.
Consensus
Buy4.28 / 5.00
Avg. Target
C$849.32
+9.6% Upside
Current Price
C$774.61
Last close
Analyst Breakdown (25 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.0%
Annualized
90-Day Vol
29.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$938.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$832.99 | C$756.32 – C$917.42 |
| 60 trading days | C$884.07 | C$771.24 – C$1013.41 |
| 90 trading days | C$938.29 | C$793.81 – C$1109.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Regeneron's advancements in gene therapy and its participation in discussions about regulatory standards for rare diseases, as these factors may enhance its growth prospects.
Regeneron’s Market Cap Hits $80.8 Billion
With a market cap of $80.8 billion and a P/E ratio of 19.42, Regeneron remains a significant player in the biotech industry, reflecting investor confidence in its future growth.
Bull case
The recent FDA workshop on evidence standards for rare diseases could create more flexible regulatory paths, which may benefit Regeneron's pipeline of therapies aimed at rare conditions. Plus, the growing in vivo gene editing market offers significant opportunities for the company.
Bear case
Even with positive momentum, investors should stay cautious about potential setbacks in clinical trials or regulatory approvals, as these could affect Regeneron's growth trajectory. Increased competition in the biotech space also poses a risk.
Positive Regulatory Developments
Advertisement
The FDA, in collaboration with the Duke-Margolis Institute, is hosting a workshop focused on evidence standards for rare diseases. This initiative aims to tackle the challenges of conducting clinical trials in small patient populations, which could lead to more favorable regulatory conditions for therapies like those developed by Regeneron.
Growth in Gene Editing Market
The global in vivo gene editing market is projected to grow significantly, reaching $22.6 billion by 2036. Regeneron is well-positioned to capitalize on this growth, particularly with its involvement in innovative therapies targeting genetic disorders and rare diseases.
Market Performance and Investor Sentiment
Regeneron's stock performance reflects strong investor sentiment, with a market cap of $80.8 billion and a P/E ratio indicating solid valuation. The company's commitment to advancing gene therapies aligns with increasing market demand for innovative healthcare solutions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
